Navigation Links
Research Reveals Why Tamoxifen Doesn't Always Work

Receptors on the surface of breast cancer cells may be the key, scientists say

THURSDAY, Oct. 30 (HealthDay News) -- Scientists have uncovered new clues to how breast cancer cells become resistant to the widely-used prevention and treatment drug tamoxifen.

The findings, from a team at Georgetown University Medical Center (GUMC), in Washington, D.C., could provide a way to identify tamoxifen users who have become resistant, so that doctors can try a better treatment option sooner.

According to the study, tamoxifen-resistant breast cancer cells display few of the "alpha" estrogen receptors that the drug is designed to bind with and inhibit. Instead, they display many more "gamma" estrogen-related receptors, which tamoxifen appears to activate, the researchers said.

The Georgetown group also tracked how, as tamoxifen resistance increases, breast cancer cells gradually lose their alpha receptors while gaining more estrogen-related gamma receptors.

The study, published in the Nov. 1 issue of the journal Cancer Research, offers two important new insights, according to lead author Rebecca Riggins, research assistant professor of oncology at GUMC's Lombardi Comprehensive Cancer Center.

First, it gives a clearer understanding of the importance of the gamma estrogen-related receptor in breast cancer.

"Until now, this receptor has not been viewed to be of much importance in any type of breast cancer. All that was known is that there were more of these receptors in breast cancer than in normal breast tissue, we hadn't got much further than that," Riggins said in a GUMC news release.

The findings could also help explain why invasive lobular carcinoma -- the subtype of breast cancer examined in this study -- may not respond as well to tamoxifen as other breast cancer subtypes.

"It is unclear whether tamoxifen is very effective in this cancer, and has been a point of debate among clinicians. This study is a good first step toward clarifying the role that tamoxifen resistance apparently plays in treatment of invasive lobular cancer," Riggins said.

More information has more about tamoxifen.

-- Robert Preidt

SOURCE: Georgetown University Medical Center, news release, Oct. 30, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
Related Image:
Research Reveals Why Tamoxifen Doesn't Always Work
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (ASI) as their exclusive channel partner for the Nutraceutical Specialties products into oral ... the US, effective immediately. , “We are pleased to announce our expanded ...
(Date:11/30/2015)... ... 2015 , ... Medicalis, a leading developer of enterprise-scale Imaging ... (RSNA) annual meeting, being held November 29 – December 3, 2015, that its ... company has completed installations for Integrated Delivery Network (IDN) customers such as WellSpan, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and ... Mesh technology for soft tissue repair in the US via Insightra’s national direct ... surgical mesh intended to support and reinforce soft tissue for 6-9 months before ...
(Date:11/30/2015)... ... ... TransPack Volume 6 features 30 customizable transitions created exclusively for use within ... with blur & drop shadow options. Utilize the controls in the inspector window ... the next with TransPack's easily customizable styles. , TransPack Volume 6 features ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Royal Philips (NYSE: PHG ... first MRI guided user interface and automatic scan parameter ... MR Conditional implants, such as knee and hip replacements, ... Society of North America Annual Meeting (RSNA) . The ... confidence of this growing patient population. ScanWise Implant adds ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... in 2014, and is expected to grow at a CAGR of ... was valued at USD 135.6 million in 2014, and ... to 2020. --> According to the new Market Research ... Minimally invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - ...
(Date:11/30/2015)... the Six Months Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , 518,852 ... , 384,242 , 9.8 Hospital Management ... , (18.3) Medical Insurance Administration Service Income , ... Medical Devices and Accessories Sales , 89,645 , ... 2,822 , 2,917 , (3.3) ...
Breaking Medicine Technology: